Back

Outcomes associated with sodium glucose co-transporter 2 inhibitors in anticoagulated atrial fibrillation patients

16 April 2023 (08:00 - 20:00)
Organised by:
Congress Presentation Part of: Atrial Fibrillation - Round 6 - Mechanisms - Pathophysiology Epidemiology, Prognosis, Outcome EHRA Premium Access EHRA 2023

About the speaker

Photo
Doctor Ameenathul Mazaya Fawzy

Liverpool Heart and Chest Hospital, Liverpool (United Kingdom of Great Britain & Northern Ireland)

8 More presentations in this session

Presentation thumbnail
Associations of general and abdominal obesity, and genetic risk with atrial fibrillation: longitudinal analyses in the UK biobank study
Doctor S. Choi (Seoul, KR)
Abstract Slides
Presentation thumbnail
Patterns of pulmonary vein activity that may help identify patients who need further ablation beyond pulmonary vein isolation in persistent AF
Doctor Y. Prudat (Lausanne, CH) Doctor P. Pascale (Lausanne, CH)
Abstract
Presentation thumbnail
Volumetric quantification of peri-atrial fat inflammation in atrial fibrillation patients
Doctor K. Vickneson (Edinburgh, GB)
Abstract Slides
Presentation thumbnail
Myeloperoxidase causes both arrhythmogenic structural and electrical remodelling in neonatal rat ventricular myocyte monolayers
Mrs R. Al-Shama (Amsterdam, NL)
Abstract Slides
Presentation thumbnail
Clustering of cardiovascular and renal comorbidities and risk of incident atrial fibrillation in the community-based PREVEND cohort
Miss C. Van Deutekom (Groningen, NL)
Abstract Slides

Access the full session

Session thumbnail
Atrial Fibrillation - Round 6 - Mechanisms - Pathophysiology

The Event

Event poster

EHRA 2023

16 April - 18 April 2023

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources